United States, Nevada, Las Vegas, DelveInsight’s ‘Short Bowel Syndrome Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Short Bowel Syndrome therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Short Bowel Syndrome pipeline domain.
Key Takeaways from the Short Bowel Syndrome Pipeline Report
Short Bowel Syndrome Overview
Short bowel syndrome (SBS) in adults is defined as less than 180 to 200 centimeters of remaining small bowel (normal length 275 to 850 cm) leading to the need for nutritional and fluid supplements. Short bowel syndrome may be classified as a cause or subcategory of intestinal failure. In rare cases, infants are born with a short bowel (congenital short bowel syndrome). Although these congenital cases are often associated with malrotation of the small intestine, the exact cause of congenital short bowel syndrome is unknown. The main cause of short bowel syndrome is surgery to remove a portion of the small intestine. This surgery can treat intestinal diseases, injuries, or birth defects. Some children are born with an abnormally short small intestine or a missing part of their bowel, which can cause short bowel syndrome. In infants, short bowel syndrome most commonly occurs following surgery to treat necrotizing enterocolitis, a condition in which part of the tissue in the intestines is destroyed
Short Bowel Syndrome Pipeline Analysis: Drug Profile
Glepaglutide: Zealand Pharma
Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is being developed as a liquid product in an autoinjector designed for subcutaneous administration, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. Currently the product is in Phase III stage of development for the treatment of Short Bowel Syndrome
Discover more about the emerging Short Bowel Syndrome drugs @ Short Bowel Syndrome Treatment Drugs
Short Bowel Syndrome Key Companies
Short Bowel Syndrome Pipeline Therapies
Short Bowel Syndrome Pipeline Therapeutics Assessment
Scope of the Short Bowel Syndrome Pipeline Report
Find out more about the Short Bowel Syndrome treatment options in development @ Short Bowel Syndrome Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Request for a sample report to know more about the leading companies working in the Short Bowel Syndrome pipeline domain.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/